Research programme: hepatitis B therapeutics - Maxwell Biosciences
Latest Information Update: 22 Nov 2022
At a glance
- Originator Maxwell Biosciences
- Class Antivirals; Peptoids
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 12 Oct 2022 Maxwell Biosciences has patent protection for Hepatitis B therapeutics in USA (Maxwell Biosciences website, October 2022)
- 07 Oct 2022 Early research in Hepatitis B in USA (unspecified route) (Maxwell Biosciences pipeline, October 2022)